# International Agency for Research on Cancer



Governing Council Sixty-first Session GC/61/15 15/05/2019

Lyon, 16–17 May 2019 Auditorium

#### APPOINTMENT OF NEW MEMBERS OF THE SCIENTIFIC COUNCIL

- 1. In accordance with Article VI of the Statute and Resolution GC/57/R18, the term of office of ten members of the Scientific Council, namely Drs Boris Alekseev (Russian Federation), Jonas Bergh (Sweden), Jenny Chang-Claude (Germany), Jerome Coffey (Ireland), Eugenia Dogliotti (Italy), Karima El Rhazi (Morocco), Kadir Mutlu Hayran (Turkey), Lalit Kumar (India), Dukhyoung Lee (Republic of Korea) and Giske Ursin (Norway) will be completed with the 2019 meeting of the Governing Council.
- 2. For the information of the Council, this leaves the following 16 members (9 women and 7 men) still serving on the Scientific Council: Drs Adèle Green (Australia), Atsushi Ochiai (Japan), Roberto Salgado (Belgium), Pilar Sánchez Gómez (Spain) and Simon Tavaré (UK) until 2020; Drs Salha Bujassoum Al Bader (Qatar), Jacqueline Clavel (France), Christine Friedenreich (Canada), Maria Sibilia (Austria) and João Viola (Brazil) until 2021; and Drs Hendriek Boshuizen (Netherlands), James Robert Cerhan (USA), Janne Mikael Pitkäniemi (Finland), Sabine Rohrmann (Switzerland), Anne Tjønneland (Denmark) and Kazem Zendehdel, Iran (Islamic Republic of) until 2022.
- 3. The areas of expertise of those members remaining on the Scientific Council is provided below for consideration by the Governing Council in making its selection of new Scientific Council members from among the nominations.

Name	Country	Term of office	Gender	Field of expertise
Adèle Green	Australia	2017 – 2020	F	Cancer etiology, prevention and implementation research, health services and policy
Atsushi Ochiai	Japan	2017 – 2020	M	Mechanisms of cancer progression, tumour microenvironment, cancer therapeutics
Roberto Salgado	Belgium	2017 – 2020	M	Molecular pathology, solid tumours, in particular breast cancer, circulating tumour biomarkers, next generation sequencing technologies, validation of biomarkers, innovative clinical trials incorporating genomics, quality assurance of genomic technologies
Pilar Sánchez Gómez	Spain	2017 – 2020	F	Brain tumours, preclinical tests, cancer therapeutics, molecular pathology, tumour microenvironment

Name	Country	Term of office	Gender	Field of expertise
Simon Tavaré	UK	2017 – 2020	М	Cancer genomics, evolutionary approaches to cancer, statistical bioinformatics for arrays and sequencing, computational biology, population genetics
Salha M. Bujassoum Al Bader	Qatar	2018 – 2021	F	Oncology, breast cancer, cancer screening
Jacqueline Clavel	France	2018 – 2021	F	Environmental epidemiology, childhood cancer, cancer registries
Christine Friedenreich	Canada	2018 – 2021	F	Cancer etiology, prevention and survival, physical activity
Maria Sibilia	Austria	2018 – 2021	F	Molecular medicine, tumour immunology, inflammation
João P.B. Viola	Brazil	2018 – 2021	M	Tumour immunology, cancer cell transformation
Dr Hendriek Boshuizen	NL	2019 – 2022	F	Public health indicators (Health expectancy, DALYs), mathematical models and statistical methods, nutritional cancer epidemiology, socio-economic and geographic differentials in health, cost-efficacy of preventive interventions
Dr James Robert Cerhan	USA	2019 – 2022	M	Environmental, lifestyle, genetic and biologic factors in the etiology of lymphomas as well as myeloid, breast, endometrial, colorectal and prostate cancers, lifestyle, genetic, tumour/microenvironment and treatment factors in lymphoma patients that predict outcomes and quality of life
Dr Janne Mikael Pitkäniemi	Finland	2019 – 2022	M	Biostatistics, epidemiology, statistical methods in genetic epidemiology, cancer registration
Dr Sabine Rohrmann	Switzerland	2019 – 2022	F	Diet/lifestyle and cancer risk, energy metabolism and components of the metabolic syndrome and their associations with cancer risk, factors influencing progression and survival of cancer patients
Dr Anne Tjønneland	Denmark	2019 – 2022	F	Nutritional and cancer epidemiology

Name	Country	Term of office	Gender	Field of expertise
Dr Kazem Zendehdel	Iran I.R.	2019 – 2022	М	Cancer epidemiology, cancer registration, implementation science and public health programmes, cancer prevention and early detection programmes, molecular and genetic epidemiology, clinical epidemiology, population-based survival, disease registry programmes
			TOTAL	
			F = 9	
			M = 7	

4. In accordance with Article VI.2 of the Agency's Statute, the Governing Council is requested to select new members to be appointed to the Scientific Council from the attached list of experts, one each from Germany, India, Ireland, Italy, Morocco, Norway, Republic of Korea, Russian Federation and Sweden.

## **GERMANY**

Bremen

Professor Dr Ulrike Haug Leibniz Institute for Prevention Research and Epidemiology – BIPS Head of Department Clinical Epidemiology

Field: Cancer epidemiology, pharmacoepidemiology and molecular epidemiology, evaluation of molecular markers for early cancer detection and colorectal cancer screening.

Professor Rudolf Kaaks Head, Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Heidelberg

**Field:** Cancer epidemiology with focus on metabolic, hormonal and genetic determinants of cancer risk, molecular markers for early cancer detection and risk stratification, and cancer screening (lung, prostate).

### **INDIA**

Dr Neerja Bhatla Department of Obstetrics & Gynaecology All India Institute of Medical Sciences New Delhi

Field: Cancer screening and prevention.

Professor Ravi Mehrotra

Director

ICMR – National Institute of Cancer

Prevention and Research

Department of Health Research

Noida

**Field:** Cancer prevention, epidemiology, pathology and public health.

#### **IRELAND**

Professor William Gallagher University College Dublin (UCD), School of Biomolecular and Biomedical Science, Dublin

Field: Molecular oncology, precision medicine, breast cancer, prostate cancer, melanoma, next-generation sequencing technology, biomarker validation, molecular pathology, diagnostic assays, preclinical evaluation of novel anti-cancer agents.

Professor William Watson University College Dublin (UCD) School of Medicine, Conway Institute, Dublin

**Field:** Prostate cancer, translational and clinical research.

#### **ITALY**

Dr Alessandra Carè Center for Gender-specific Medicine Istituto Superiore di Sanità, Rome

Field: Cellular and molecular oncology.

Dr Pietro Pichierri Department of Environment and Health Istituto Superiore di Sanità, Rome

**Field:** Experimental and computational carcinogenesis.

#### **MOROCCO**

Dr Karima Bendahhou Head, Cancer registry of Casablanca

Field: Epidemiology and statistics.

Professor Karim Ouldim Director Cancer Research Institute, Fez

**Field:** Medical genetics related to mental diseases, cancer and oncogenetics.

#### **NORWAY**

Professor Tone Bjørge Head, Epidemiology & Medical Statistics Section, University of Bergen Researcher, Cancer Registry of Norway

Field: Cancer and metabolic syndrome, micronutrient, birth characteristics among children and adolescents, pregnancy and maternal cancer, long-term consequences/adverse health effects of cancer in childhood and adolescence, cervical cancer epidemiology, screening, global burden of diseases.

#### REPUBLIC OF KOREA

Professor Jong Bae Park
Dean, National Cancer Center-Graduate School
of Cancer Science of Policy
National Cancer Center, Seoul

**Field:** MicroRNA, mechanisms of carcinogenesis.

#### RUSSIAN FEDERATION

Professor Evgeny V. Kovalevskiy Federal State Budgetary Scientific Institution "Izmerov Research Institute of Occupational Health", Moscow

**Field:** Occupational and environmental cancer epidemiology, cancer control, prevention and registration.

Dr Sergey A. Ivanov A. Tsyb Medical Radiological Research Centre Obninsk

Field: Oncology, medical radiology, urology.

## **SWEDEN**

Dr Anders Bjartell
Department of Urology
Skåne University Hospital Malmö
Departmentt of Translational Medicine
Division of Urological Cancers
Faculty of Medicine, Lund University

Field: Urology.

Professor Gunilla Enblad Uppsala University

**Field:** Clinical and tumour biological studies of malignant lymphomas. Immunotherapy.

NB: The curricula vitae will be distributed to Governing Council members only.